Literature DB >> 30542670

Targeting ELK1: a wELKome addition to the prostate cancer armamentarium.

Jelani C Zarif1,2, Emmanuel S Antonarakis1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30542670      PMCID： PMC6287613          DOI： 10.21037/amj.2018.10.08

Source DB:  PubMed          Journal:  AME Med J        ISSN： 2520-0518


× No keyword cloud information.
  11 in total

1.  Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.

Authors:  Peter S Nelson
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

2.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Mary Nakazawa; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

3.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

4.  Biology and evolution of poorly differentiated neuroendocrine tumors.

Authors:  David S Rickman; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Med       Date:  2017-06-06       Impact factor: 53.440

5.  Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Authors:  Nora M Navone; Wytske M van Weerden; Robert L Vessella; Elizabeth D Williams; Yuzhuo Wang; John T Isaacs; Holly M Nguyen; Zoran Culig; Gabri van der Pluijm; Cyril A Rentsch; Rute B Marques; Corrina M A de Ridder; Lukas Bubendorf; George N Thalmann; William Nathaniel Brennen; Frédéric R Santer; Patrizia L Moser; Peter Shepherd; Eleni Efstathiou; Hui Xue; Dong Lin; Jeroen Buijs; Tjalling Bosse; Anne Collins; Norman Maitland; Mark Buzza; Michelle Kouspou; Ariel Achtman; Renea A Taylor; Gail Risbridger; Eva Corey
Journal:  Prostate       Date:  2018-08-02       Impact factor: 4.104

Review 6.  Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Authors:  E S Antonarakis; A J Armstrong; S M Dehm; J Luo
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-17       Impact factor: 5.554

7.  Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.

Authors:  Rayna Rosati; Lisa Polin; Charles Ducker; Jing Li; Xun Bao; Dakshnamurthy Selvakumar; Seongho Kim; Besa Xhabija; Martha Larsen; Thomas McFall; Yanfang Huang; Benjamin L Kidder; Andrew Fribley; Janice Saxton; Hiroki Kakuta; Peter Shaw; Manohar Ratnam
Journal:  Clin Cancer Res       Date:  2018-09-05       Impact factor: 12.531

Review 8.  The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.

Authors:  Jelani C Zarif; Cindy K Miranti
Journal:  Cell Signal       Date:  2016-01-29       Impact factor: 4.315

9.  Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.

Authors:  Jelani C Zarif; Laura E Lamb; Veronique V Schulz; Eric A Nollet; Cindy K Miranti
Journal:  Oncotarget       Date:  2015-03-30

10.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.

Authors:  Himisha Beltran; Davide Prandi; Juan Miguel Mosquera; Matteo Benelli; Loredana Puca; Joanna Cyrta; Clarisse Marotz; Eugenia Giannopoulou; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally; Scott A Tomlins; David M Nanus; Scott T Tagawa; Eliezer M Van Allen; Olivier Elemento; Andrea Sboner; Levi A Garraway; Mark A Rubin; Francesca Demichelis
Journal:  Nat Med       Date:  2016-02-08       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.